NASDAQ:TENX Tenax Therapeutics Q3 2026 Earnings Date & Estimates $1.76 -0.08 (-4.08%) As of 10:52 AM Eastern This is a fair market value price provided by Massive. Learn more. Tenax Therapeutics is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. The conference call is scheduled for November 12, 2026 at 12:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 11, 2026Conference Call DateNovember 12, 2026Conference Call12:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Tenax Therapeutics in Q3 2026Tenax Therapeutics is expected to post earnings of -$0.35 per share. In the same quarter a year earlier Tenax Therapeutics reported -$0.40 per share. Tenax Therapeutics last reported on July 31, 2026, posting -$0.35 per share and beating the -$0.3813 consensus estimate. Tenax Therapeutics has beaten the consensus EPS estimate in 8 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.35Prior-Year EPS-$0.40Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.35 (Beat by +$0.0313)EPS Beat Rate8 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Tenax Therapeutics Q3 2026 Earnings FAQ When does Tenax Therapeutics report Q3 2026 earnings? Tenax Therapeutics (NASDAQ:TENX) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Tenax Therapeutics' Q3 2026 earnings call? Tenax Therapeutics' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Tenax Therapeutics? Analysts expect Tenax Therapeutics to post earnings of -$0.35 per share for Q3 2026. Tenax Therapeutics Earnings HeadlinesLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of December 28, 2026 in Tenax Therapeutics, Inc. Lawsuit - TENX39 minutes ago | prnewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Tenax Therapeutics, Inc. and Certain Officers – TENXNovember 3 at 5:23 PM | globenewswire.comThe most dangerous moment in a financial crisisDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.November 4 at 1:00 AM | Weiss Ratings (Ad)SueWallSt Reminds Tenax Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of December 28, 2026 - TENXNovember 3 at 10:06 AM | globenewswire.comTENX Investors Have Opportunity to Lead Tenax Therapeutics, Inc. Securities Fraud LawsuitNovember 2 at 6:12 PM | prnewswire.comSecurities Fraud Lawsuit Filed Against Tenax Therapeutics, Inc.: The Law Offices of Frank R. Cruz Outlines Lead Plaintiff DeadlineNovember 2 at 5:07 PM | businesswire.comSee More Tenax Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tenax Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tenax Therapeutics and other key companies, straight to your email. Email Address About Tenax TherapeuticsTenax Therapeutics (NASDAQ:TENX) is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and pulmonary diseases. The company’s research programs are aimed at addressing conditions with significant unmet medical needs, including pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). Tenax’s lead product candidate is TNX-103, an oral formulation of levosimendan. Levosimendan is a calcium sensitizer and potassium-channel activator that has been approved for certain heart-failure indications outside the United States. Tenax is evaluating the therapy for potential use in patients with PH-HFpEF, an area in which treatment options remain limited. The company’s activities are primarily focused on clinical development and regulatory advancement in the United States. Tenax Therapeutics was formerly known as Oxygen Biotherapeutics and adopted its current name as it shifted its focus toward pharmaceutical development in cardiovascular and pulmonary medicine.View Tenax Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Advanced Micro Devices' Q3 Results Answer a Big Question, But Another Remains3 Dividend Increases Above 10%, But Which Offers the Most Income?High Voltage Returns: Talen Energy Powers the Data Center RushMarriott's Earnings Beat Shows Why It's More Than a Bet on Travel DemandPalantir's $2.3 Billion Quarter Puts Its Premium Valuation to the TestTower Semiconductor's Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?Apple's Earnings Beat Comes With a Catch for Investors Heading Into the Holidays Upcoming Earnings Airbnb (11/5/2026)Sony (11/5/2026)Toyota Motor (11/5/2026)Monster Beverage (11/5/2026)Canadian Natural Resources (11/5/2026)ConocoPhillips (11/5/2026)Devon Energy (11/5/2026)EOG Resources (11/5/2026)Targa Resources (11/5/2026)TC Energy (11/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
